| ID Source | ID |
|---|---|
| PubMed CID | 101658256 |
| MeSH ID | M0225813 |
| Synonym |
|---|
| 154277-21-1 |
| cypemycin , |
Cypemycin is a parent linaridin peptide known to contain nonproteinogenic dehydrobutyrine. It is produced by Streptomyces sp.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Cypemycin is a parent linaridin peptide known to contain nonproteinogenic dehydrobutyrine, " | ( Reconstitution of the Linaridin Pathway Provides Access to the Family-Determining Activity of Two Membrane-Associated Proteins in the Formation of Structurally Underestimated Cypemycin. Liu, W; Wang, X; Xue, Y, 2023) | 2.55 |
| "Cypemycin is an extensively modified linear peptide produced by Streptomyces sp." | ( Genome mining and genetic analysis of cypemycin biosynthesis reveal an unusual class of posttranslationally modified peptides. Bibb, M; Claesen, J, 2010) | 1.35 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (22.35) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (11.11%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (88.89%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||